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Featured Article
Bladder antimuscarinics and cognitive decline in elderly patients
Daniela Claudia Mogaa,b,c,*, Erin L. Abnerb,c, Qishan Wub, Gregory A. Jichac,d
aDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, USA
bDepartment of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA
cSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
dDepartment of Neurology, College of Medicine, University of Kentucky, Lexington, KY, USA
Abstract Introduction: The evidence on the impact of bladder antimuscarinics initiation on cognitive func-
tion in older adults is inconsistent.
Methods: A retrospective analysis of data from the National Alzheimer’s Coordinating Center
(NACC) on enrollees 65 years and older evaluated the association between antimuscarinic initiation
and cognitive decline. We defined decline from baseline (yes/no) for cognitive assessments included
in the NACC Uniform Data Set 2.0 battery. New users were matched on year of enrollment and time
in the cohort to randomly selected nonusers. Analyses were conducted using inverse probability of
treatment weights based on baseline propensity scores.
Results: Our analyses included 698 new users and 7037 nonusers. The odds ratio (OR) and 95% con-
fidence interval for cognitive decline in users as compared to nonusers was 1.4 (1.19–1.65) for Mini–
Mental State Examination (MMSE), and 1.21 (1.03–1.42) for Clinical Dementia Rating; in addition,
the odds of decline were 20% higher in users compared to nonusers for semantic memory/language
and executive function. The effect estimate for MMSEwas 1.94 (1.3–2.91) for those with mild cogni-
tive impairment, 1.26 (0.99–1.62) in those with normal cognition, and 1.44 (1.04–1.99) in those with
dementia at baseline.
Discussion: Our results show that antimuscarinic initiation is associated with cognitive decline and
raise questions about their use, especially in those with impaired cognition.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
The cholinergic system in the brain plays an important
role in working memory, attention, awareness, psychomotor
speed, and selection of relevant stimuli from the environ-
ment [1]. By blocking cholinergic receptors in the central
nervous system (CNS), drugs with anticholinergic activity
could potentially cause undesirable effects on these impor-
tant cognitive functions, depending on the drug bioavail-
ability and metabolism, as well as its ability to cross the
blood–brain barrier [2,3]. Changes in the acetylcholine-
mediated neurotransmission and the increased permeability
of the blood–brain barrier caused by aging inflate the risk of
CNS adverse effects of anticholinergic drugs. Similar effects
are the result of different comorbidities (e.g., diabetes melli-
tus, Alzheimer’s disease [AD], vascular dementia), which
are also more prevalent in the elderly population [4–6].
Previous studies showed that drugs with anticholinergic
properties could result in cognitive decline and even
precipitate dementia in older adults [7,8]. Moreover, a
recent prospective cohort study investigating the effect of
cumulative anticholinergic exposure demonstrated an
increased risk of dementia with higher use of
anticholinergics in adults aged 65 years and older [9].
Bladder antimuscarinics (referred to as antimuscarinics
hereafter), the main pharmacological option for treating
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urge and mixed urinary incontinence, are among the most
commonly used drugs with anticholinergic properties in
the elderly [9]. Of the available antimuscarinics, the most
frequently used by patients is oxybutynin, a nonselective
agent that can bind to receptors throughout the body,
including CNS [9]. Previous studies investigating the poten-
tial role of antimuscarinics in causing cognitive decline in
older adults included a small number of patients, measured
cognitive performancewith scales less sensitive to longitudi-
nal change, or followed participants for a short period and
led to inconclusive results. Some of the studies suggested
that in patients with AD, antimuscarinics produce cognitive,
behavioral, and physiological changes [10,11], but other
studies failed to support these findings [12]. The primary
objective of our study was to further evaluate the association
of antimuscarinic initiation with cognitive decline in older
adults by using the rich data collected as part of the ongoing
National Alzheimer’s Coordinating Center (NACC) cohort
and to address some of the limitations of previous studies.
2. Methods
2.1. Setting
We conducted a retrospective evaluation using data
collected as part of the prospective NACC cohort. Data ava-
ilable from the Uniform Data Set (UDS) between September
1, 2005 and December 31, 2013 were used to identify
new antimuscarinic users [13] and nonusers as controls and
conduct all of the analyses described in the following.
2.2. Participants
A description of the NACC cohort, its eligibility criteria,
and data collection are available elsewhere [14–17]. In
summary, NACC was established in 1999 with the purpose
of facilitating research related to AD. This cohort includes
not only patients with AD and related disorders but also
cognitively normal subjects and those with mild cognitive
impairment (MCI). Beginning in 2005, UDS data were
collected through standardized evaluations of enrollees
from National Institute on Aging–funded Alzheimer’s
Disease Centers (ADC). Each ADC has its own
recruitment protocol, and participants are recruited
through clinician or self-referral (patients or family mem-
bers), or through active community recruitment strategies.
Of the 32,532 participants enrolled in NACC between
2005 and beginning of 2016, about 89% were 60 years or
older, 80% were white, 70% had 12 or more years of educa-
tion, 37% had normal cognition at enrollment, about 21%
had MCI, and about 37% had dementia. In addition to the
ADC-specific inclusion/exclusion criteria, the eligibility
criteria for our investigation included (1) participants
enrolled on or after September 1, 2005 with a minimum of
one follow-up visit; (2) age 65 years and older at the
visit when antimuscarinic use was first reported (or the
equivalent visit for nonusers—see the following for
additional information regarding nonusers selection); (3)
with medication data available at all visits, and (4) with no
antimuscarinics reported at enrollment. We excluded partic-
ipants with non-MCI or non–AD-related cognitive impair-
ment, specifically (1) cognitive status categorized as
“impaired not mild cognitive impairment”; (2) frontotempo-
ral dementia; (3) primary progressive aphasia; (4) progres-
sive supranuclear palsy; (5) corticobasal degeneration; (6)
Huntington’s disease; (7) prion disease; (8) Down’s syn-
drome; (9) CNS neoplasm; (10) traumatic brain injury;
(11) hydrocephalus; (12) alcohol-related dementia; (13) de-
mentia of undetermined etiology. A flow diagram to describe
the participants’ selection process and the groups included in
the analyses is depicted in Fig. 1.
Exposure to antimuscarinics was identified from the self-
reported data collected at enrollment and yearly thereafter
using the “brown bag” medication review approach (i.e.,
the participant or a family member were asked to bring all
current medications to the research assessment) on prescrip-
tion and over-the-counter medications for the two-week
window preceding the index date [15]. Antimuscarinic expo-
sure was measured as antimuscarinics yes/no by identifying
at least one mention of the following medications: oxybuty-
nin, tolterodine, flavoxate, hyoscyamine, darifenacin,
trospium, solifenacin, fesoterodine, propantheline. Antimus-
carinic exposure was further categorized based on musca-
rinic receptor selectivity: nonselective antimuscarinics
(oxybutynin, tolterodine, flavoxate, hyoscyamine, trospium,
fesoterodine, propantheline) and M3 selective antimuscar-
inics (darifenacin or solifenacin). When exposure to more
than one antimuscarinic was reported, exposure category
was assigned as nonselective in the presence of at least
one nonselective drug. Antimuscarinic users were consid-
ered prevalent users if antimuscarinic exposure was reported
at enrollment and incident (new) users if exposure was first
Fig. 1. Inclusion/exclusion cascade and study groups. Abbreviations: BAM,
bladder antimuscarinics; IPTW, inverse probability of treatment weights;
MCI, mild cognitive impairment; NACC, National Alzheimer’s Coordi-
nating Center.
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reported at one of the follow-up visits. Prevalent users were
excluded from further analyses.
2.3. Outcome description
Cognitive function was measured based on the informa-
tion collected at follow-up UDS visits. From the compre-
hensive cognitive evaluation conducted as part of the
cohort, we selected our measures of interest based on
the evidence from prior research to suggest areas poten-
tially impacted by medications with anticholinergic prop-
erties in general, and therefore antimuscarinics. Our
outcomes included two measures of global cognitive sta-
tus—Mini–Mental State Examination (MMSE) [18] and
Clinical Dementia Rating (CDR) [19] global score. In
addition, we also evaluated the association between anti-
muscarinic initiation and decline in clinical diagnosis sta-
tus by assessing the likelihood of decline from normal to
MCI or dementia, and from MCI to dementia within 1
year from baseline. Furthermore, specific cognitive do-
mains were evaluated using the following measures: (1)
memory, orientation, and judgment domain scores from
CDR; (2) semantic memory and language using category
fluency tests (Animals and Vegetables) and Boston
Naming Test; (3) psychomotor speed using WAIS-R
Digit-Symbol Substitution and the Trail Making Test
Part A; and (4) executive function using the Trail Making
Test Part B. Detailed descriptions of these tests, including
information about score range and interpretation for the
NACC ADC cohort, are available elsewhere [17]. Decline
was identified as a dichotomous variable and was defined
considering the scoring algorithm for each cognitive
outcome. Specifically, a participant was categorized as
experiencing cognitive decline from baseline in case of a
higher score at the follow-up visit (CDR global score,
memory, orientation, and judgment domain scores from
CDR), or a lower score at follow-up visit (MMSE, Ani-
mals and Vegetables, Boston Naming Test), or a longer
time for completion at follow-up as compared to baseline
(WAIS-R Digit-Symbol Substitution, Trail Making Test
Part A, Trail Making Test Part B), as compared to their
score (or time) at baseline. We also coded decline if the
score was in the valid range at baseline but was missing
due to “cognitive/behavior problem” at follow-up. In addi-
tion, we conducted sensitivity analyses to test the robust-
ness of our outcome definition (i.e., cognitive decline)
by excluding those with missing data and using a more
conservative approach that considered decline in the pres-
ence of a clinically meaningful change based on the stan-
dard deviations for cognitively intact older adults reported
in a previous study using NACC data [17]. Specifically, we
considered two additional definitions, one where decline
was defined based on a minimum change equal to half
the reported standard deviation, and one where decline
was defined based on a minimum change equal to one re-
ported standard deviation. Because the reported standard
deviations contained decimals, we rounded up to the
next whole point to define decline.
Fig. 2. Figure shows percent with cognitive decline in antimuscarinic users and nonusers stratified by baseline cognitive status. Top panels include unadjusted
analyses; Bottom panels include adjusted (weighted) analyses.
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2.4. Statistical analysis
Analyses were conducted after the comparison group of
nonusers was selected, and we applied all eligibility criteria
for both groups. For each new user, we randomly selected
10 nonusers that were matched by year of enrollment and
time since enrollment (visit year). Baseline was defined
as the prior UDS assessment (i.e., last assessment before
the first one reporting antimuscarinic use, or the equivalent
for the nonusers group). We evaluated group differences
between antimuscarinic users and nonusers at baseline us-
ing chi-square analysis (or Fisher’s exact test where appro-
priate) for categorical variables, and t-tests for continuous
variables.
For the main analyses, the propensity score (PS)
method was used to address treatment selection bias and
to balance observed baseline covariates between the study
groups. The PS for each participant was estimated through
logistic regression as the probability of starting treatment
with an antimuscarinic during study period (i.e., report
antimuscarinic use during a UDS evaluation) based on
their characteristics measured at baseline from the stan-
dardized NACC data collection based on self-reported in-
formation or proxy respondents. The logistic regression
model to predict antimuscarinic initiation and calculate
PS included variables related to antimuscarinic use and
also variables for which empirical evidence exists to
support their impact on cognitive function [20,21].
Specifically, the model included demographic
characteristics (age, race, sex, education), living
situation, indicators for each recruiting center (ADC),
year at enrollment, year at assessment, body mass index
(BMI), lifestyle-related risk factors (hypercholesterolemia,
alcohol use, smoking), urinary and fecal incontinence sta-
tus, cognitive status (i.e., normal, MCI, or dementia), level
of independence, comorbidities (cardiovascular disease,
congestive heart failure, stroke, transient ischemic attack,
Parkinson’s disease, hypertension, diabetes, recent depres-
sion episodes, psychiatric disorders), other medications
used (antiadrenergic agents, beta blockers, diuretics, cal-
cium channel blocking agents, angiotensin-converting
enzyme inhibitors, antidepressants, antipsychotic agents,
anxiolytic, sedative, or hypnotic agents, antiparkinsonian
agents, medications approved by the Food and Drug
Administration for the treatment of AD’s cognitive symp-
toms [i.e., memantine or cholinesterase inhibitors], and to-
tal number of medications reported at visit), and
anticholinergic load measured using the anticholinergic
drug scale [22]. When calculating propensity scores, to
address the issues of missing data for some of the categor-
ical variables included in the model, missing values were
treated as a separate category.
The association between antimuscarinic exposure and
cognitive outcomes was measured based on each patient’s
change in score from baseline. The odds ratios with 95%
confidence limits for cognitive decline associated with
antimuscarinic initiation were calculated using inverse prob-
ability of treatment weights (IPTWs) with stabilized weights
based on the PS for initiating antimuscarinics and trimming
nonoverlapping regions of the PS distribution [23,24].
Analyses were conducted for all antimuscarinic users and
also after restricting the new users group to those treated
with nonselective agents. For a clinical interpretation of
the results, we also calculated the number needed to treat
to cause decline for the overall cognitive performance
measures [25]. As an exploratory analysis, we evaluated
whether the association of antimuscarinics and cognitive
decline measured through MMSE was different by cognitive
status at baseline (normal, MCI, or dementia), for all anti-
muscarinics users and also restricted to nonselective
antimuscarinics.
3. Results
Of the 29,004 participants enrolled in the NACC cohort
between September 1, 2005 and December 31, 2013, 2075
reported antimuscarinic use during follow-up. Of these,
787 participants did not report antimuscarinics at enroll-
ment, and 698 met all the eligibility criteria for the study
and were considered new antimuscarinic users for our ana-
lyses (Fig. 1). About 70% of users reported a nonselective
antimuscarinic, most commonly oxybutynin and tolterodine
(about 40% of the nonselective antimuscarinics for each). Of
those using M3 selective antimuscarinics, about 66% used
solifenacin. Of the 7870 nonusers randomly selected after
matching by year of enrollment and year of first antimuscar-
inic report, 7037 met the inclusion/exclusion criteria and
were included in our analyses (Fig. 1).
The magnitude of cognitive decline from baseline as
evaluated through MMSE and CDR was larger in antimus-
carinic users as compared to nonusers (Table 1 and Fig. 2).
When antimuscarinic users and nonusers were compared at
baseline, several significant differences were noted in the
unadjusted analyses (Table 1). New users were mostly
women, older, less likely to live in a single family resi-
dence, and more likely to need assistance. Nonusers were
healthier, with lower BMI and fewer comorbid conditions
(less likely to have diabetes, Parkinson’s disease, depres-
sion, other psychiatric diagnosis, or active fecal inconti-
nence), were taking fewer drugs, and had a lower
anticholinergic load. New users were more likely to have
hallucinations or agitation indicated at baseline and were
more frequently cognitively impaired (Table 1 and
Supplementary Table 1). After calculating the PS for
each participant and applying weights through the IPTW
method, the groups included in the analyses were balanced
on the measured confounders (Supplementary Table 2).
Similar to the unadjusted results, in the IPTW analyses
that accounted for baseline differences between groups,
new users were more likely to show statistically signifi-
cant cognitive decline in the overall cognitive status
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Table 1
Baseline and follow-up characteristics in bladder antimuscarinics users and nonusers
Characteristic Nonusers (N 5 7037) New users (N 5 698)
Baseline
Time from enrollment (days): mean (SD) 463.1 (550.1) 425.9 (535.5)
Year of enrollment: n (%)
2005 845 (12.01) 87 (12.46)
2006 2855 (40.57) 279 (39.97)
2007 1448 (20.58) 149 (21.35)
2008 696 (9.89) 62 (8.88)
2009 521 (7.40) 51 (7.31)
2010 390 (5.54) 39 (5.59)
2011 186 (2.64) 20 (2.87)
2012 96 (1.36) 11 (1.58)
Age: mean (SD) 76.98 (7.63) 77.88 (7.15)
Male: n (%) 2993 (42.53) 289 (41.40)
Race: n (%)
White 5784 (82.19) 584 (83.67)
Black 831 (11.81) 82 (11.75)
Other 422 (6.00) 32 (4.58)
Education: n (%)
High school or less 2054 (29.19) 199 (28.51)
College degree 2883 (40.97) 282 (40.40)
Graduate degree 2100 (29.84) 217 (31.09)
Living situation: n (%)
Lives alone 1903 (27.04) 202 (28.94)
Lives with spouse or partner 4171 (59.27) 412 (59.03)
Lives with relative or friend 655 (9.31) 55 (7.88)
Lives with group 129 (1.83) 16 (2.29)
Other or unknown 179 (2.54) 13 (1.86)
Residence type: n (%)
Single family residence 6051 (85.99) 565 (80.95)
Retirement community 585 (8.31) 80 (11.46)
Assisted living/boarding home/adult family home 177 (2.52) 31 (4.44)
Skilled nursing facility/nursing home 113 (1.61) 6 (0.86)
Unknown 111 (1.58) 16 (2.29)
Level of independence: n (%)
Able to live independently 4546 (64.60) 394 (56.45)
Requires some assistance with complex activities 1486 (21.12) 198 (28.37)
Requires some assistance with basic activities 733 (10.42) 87 (12.46)
Completely dependent 272 (3.87) 19 (2.72)
BMI category: n (%)
Normal 2356 (33.48) 210 (30.09)
Overweight 2512 (35.70) 231 (33.09)
Obese 1332 (18.93) 162 (23.21)
Underweight 86 (1.22) 8 (1.15)
Unknown 751 (10.67) 87 (12.46)
Smoking history—100 lifetime cigarettes: n (%) 3289 (46.74) 318 (45.56)
Alcohol abuse: n (%) 355 (5.04) 35 (5.01)
Comorbidities: n (%)
Hypercholesterolemia 4016 (57.07) 399 (57.16)
Cardiovascular disease 555 (7.89) 56 (8.02)
Diabetes 916 (13.02) 110 (15.76)
Parkinson’s disease 134 (1.90) 45 (6.45)
Depression 1923 (27.33) 233 (33.38)
Psychiatric diagnosis 360 (5.12) 51 (7.31)
Stroke 428 (6.08) 51 (7.31)
Urinary incontinence (active) 408 (5.80) 59 (8.45)
Fecal incontinence (active) 460 (6.54) 60 (8.60)
Number of medications reported at visit: mean (SD) 5.68 (3.72) 6.44 (4.19)
Anticholinergic burden: mean (SD) 0.66 (1.12) 0.91 (1.34)
Other medications: n (%)
Antiadrenergic agent 598 (8.50) 93 (13.32)
Beta-adrenergic blocking agent 1587 (22.55) 174 (24.93)
Angiotensin-converting enzyme inhibitor 1357 (19.28) 138 (19.77)
(Continued )
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Table 1
Baseline and follow-up characteristics in bladder antimuscarinics users and nonusers (Continued )
Characteristic Nonusers (N 5 7037) New users (N 5 698)
Antidepressant 1732 (24.61) 227 (32.52)
Antipsychotic agent 286 (4.06) 33 (4.73)
Anxiolytic, sedative, or hypnotic agent 676 (9.61) 102 (14.61)
Antiparkinson agent 244 (3.47) 69 (9.89)
Medication for Alzheimer’s disease symptoms 2134 (30.33) 249 (35.67)
Diuretic 1280 (18.19) 128 (18.34)
Calcium channel blocking agent 1096 (15.57) 121 (17.34)
Hallucinations: n (%) 242 (3.44) 32 (4.58)
Delusions: n (%) 555 (7.89) 56 (8.02)
Agitation 1260 (17.91) 150 (21.49)
Cognitive status: n (%)
Normal 3269 (46.45) 259 (37.11)
MCI 1306 (18.56) 151 (21.63)
Dementia 2462 (34.99) 288 (41.26)
Mini–Mental State Examination: mean (SD)
All 25.24 (6.12) 25.46 (5.09)
Baseline cognitive status: normal 28.82 (1.54) 28.82 (1.40)
Baseline cognitive status: MCI 26.88 (2.65) 26.97 (2.74)
Baseline cognitive status: dementia 19.42 (7.01) 21.52 (5.56)
Mini–Mental State Examination: n (%)
Normal 3985 (56.63) 363 (52.01)
Mild impairment 1646 (23.39) 216 (30.95)
Moderate impairment 833 (11.84) 77 (11.03)
Severe impairment 266 (3.78) 13 (1.86)
Missing 307 (4.36) 29 (4.15)
Clinical Dementia Rating Global score: n (%)
No impairment 3119 (44.32) 249 (35.67)
Questionable impairment 2055 (29.20) 251 (35.96)
Mild impairment 1168 (16.60) 143 (20.49)
Moderate impairment 460 (6.54) 48 (6.88)
Severe impairment 235 (3.34) 7 (1.00)
Follow-up
Mini–Mental State Examination: mean (SD)
All 24.70 (6.64) 24.26 (6.21)
Baseline cognitive status: normal 28.72 (1.72) 28.68 (1.53)
Baseline cognitive status: MCI 26.22 (3.33) 25.98 (3.29)
Baseline cognitive status: dementia 17.72 (7.17) 19.04 (6.42)
Mini–Mental State Examination: n (%)
Normal 3730 (53.01) 321 (45.99)
Mild impairment 1388 (19.72) 173 (24.79)
Moderate impairment 973 (13.83) 124 (17.77)
Severe impairment 350 (4.97) 23 (3.30)
Cognitive or behavioral problems 83 (1.18) 6 (0.86)
Missing 513 (7.29) 51 (7.31)
Clinical Dementia Rating Global score: n (%)
No impairment 3003 (42.67) 227 (32.52)
Questionable impairment 1777 (25.25) 208 (29.80)
Mild impairment 1110 (15.77) 147 (21.06)
Moderate impairment 718 (10.20) 86 (12.32)
Severe impairment 429 (6.10) 30 (4.30)
Cognitive decline (Mini–Mental State Examination): n (%)
Including decline based on information regarding missing 3600 (51.15) 416 (59.60)
Including only those with available data 2972 (46.71) 356 (56.15)
Baseline cognitive status: normal 1137 (34.78) 101 (39.00)
Baseline cognitive status: MCI 668 (51.15) 92 (60.93)
Baseline cognitive status: dementia 1795 (72.91) 223 (77.43)
Abbreviations: SD, standard deviation; MCI, mild cognitive impairment.
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(Table 2) as measured by MMSE (odds ratio [OR] 5 1.4,
95% confidence interval [CI]: 1.19–1.65) and CDR
(OR 5 1.21, 95% CI: 1.03–1.42). In addition, the associ-
ation with decline on different specific cognitive domains
was statistically significant in the areas of memory
(OR 5 1.27, 95% CI: 1.05–1.52) and orientation
(OR 5 1.25, 95% CI: 1.04–1.51) domains of CDR, se-
mantic memory/languages as measured by category
fluency tests (Vegetable Naming: OR 5 1.23, 95% CI:
1.05–1.44), and executive function as measured by
the Trail Making Test Part B (OR 5 1.23, 95% CI:
1.08–1.51). Our sensitivity analyses including the more
conservative outcome definitions supported the results of
our main analyses (Supplementary Table 3). In our
exploratory analyses, when evaluating the association
with decline on MMSE stratified by cognitive status at
baseline, although not statistically significantly different,
the effect estimate was larger for those with MCI at base-
line (OR 5 1.94, 95% CI: 1.3–2.91), then in those with
normal cognition (OR 5 1.26, 95% CI: 0.99–1.62), or de-
mentia (OR 5 1.44, 95% CI: 1.04–1.99). In addition, the
effect estimate for MMSE decline was larger when ana-
lyses were restricted to new users of nonselective anti-
muscarinics (Table 2). The estimated numbers needed to
treat to produce a harmful effect (NNH) (i.e., cognitive
decline) in one participant were NNH 5 22 (95% CI:
12–142) for decline in the CDR global score, and
NNH 5 13 (95% CI: 9–24) for decline in MMSE,
with the smallest number in those with MCI at
baseline: NNH 5 7 (95% CI: 3–16) (Table 3). These re-
sults indicate that for every 22 patients treated with
antimuscarinics, one would experience decline in the
CDR global score; similarly, for every 13 patients treated
with antimuscarinics, or for every 7 patients with MCI at
baseline treated with antimuscarinics, one would experi-
ence decline as measured by MMSE.
4. Discussion
Using the rich data collected as part of the ongoing
NACC cohort, our study evaluated the association between
antimuscarinic initiation and odds of decline on various
cognitive measures in older adults. Our analyses showed
that, after controlling for baseline differences between
groups, participants who initiated an antimuscarinic were
statistically significantly more likely to exhibit cognitive
decline as compared to nonusers. Specifically, antimuscar-
inic initiators experienced decline when cognitive function
was measured with overall measures, and also they showed
decline in cognitive domains for which there is biological
plausibility for such an effect. To further investigate this as-
sociation, we investigated and identified a potentially stron-
ger negative effect on cognitive function when restricting
our analyses to those using nonselective antimuscarinics.
In terms of the clinical impact, a previous study estimated
that 32 patients (95% CI: 17–125) needed to be treated to
obtain improvement in urinary incontinence in one patient
after 90 days of treatment [12]. In this context, our esti-
mates for the NNH for different cognitive outcomes are
striking and raise important concerns with these drugs by
suggesting that we need to treat only a small number of pa-
tients to detect cognitive decline in one, and more patients
Table 2
Cognitive decline (any decline) associated with bladder antimuscarinics use
Cognitive domain Cognitive test IPTW*—all users, OR (95% CI) IPTW*—NS users, OR (95% CI)
Overall cognitive status Mini–Mental State Examination
Overall 1.4 (1.19–1.65) 1.54 (1.26–1.89)
By baseline cognitive function
Normal 1.26 (0.99–1.62) 1.42 (1.05–1.92)
Mild cognitive impairment 1.94 (1.3–2.91) 1.73 (1.03–2.92)
Dementia 1.44 (1.04–1.99) 1.76 (1.17–2.67)
Clinical Dementia Rating
Global score 1.21 (1.03–1.42) 1.22 (1.01–1.48)
Memory 1.27 (1.05–1.52) 1.32 (1.05–1.65)
Orientation 1.25 (1.04–1.51) 1.36 (1.09–1.7)
Judgment 1.08 (0.9–1.31) 1.12 (0.88–1.41)
Semantic memory/language Category fluency
Animals 1.1 (0.94–1.29) 1.14 (0.94–1.39)
Vegetables 1.23 (1.05–1.44) 1.19 (0.97–1.44)
Boston 1.13 (0.96–1.32) 1.17 (0.96–1.42)
Psychomotor speed WAIS-R Digit Symbol 1.04 (0.88–1.23) 1.09 (0.89–1.33)
Trail A 1.11 (0.95–1.31) 1.16 (0.95–1.42)
Executive function Trail B 1.23 (1.08–1.51) 1.16 (0.95–1.43)
Abbreviations: IPTW, inverse probability of treatment weights; OR, odds ratio; CI, confidence interval; NS, nonselective; ADC, Alzheimer’s Disease Centers.
*Propensity score used to calculate stabilized weights for IPTW included indicators for each ADC, year of enrollment and time from enrollment, sociodemo-
graphic information (age, sex, race, education, residence type, and living situation), level of dependency, behavioral risk factors (body mass index, alcohol,
smoking), comorbidities (urinary and fecal incontinence, cardiovascular conditions, diabetes, Parkinson’s disease, depression, stroke, psychiatric diagnosis),
number of and other medications used, anticholinergic burden.
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to see improvement in one. Importantly, the potential for an
even larger effect if antimuscarinics are prescribed to pa-
tients with MCI are to be considered in the clinical
decision-making process.
Our results are in line with other studies that previously
investigated the relationship between antimuscarinic initia-
tion and cognitive decline. A single-blind crossover design
study on nine patients with ADmeasuredMMSE, the Neuro-
psychiatric Inventory, and the Memory and Behavior Prob-
lems Checklist on and off antimuscarinics and showed that
antimuscarinics produce cognitive, behavioral, and physio-
logical changes; moreover, the study showed that antimus-
carinics with stronger anticholinergic activity were
associated with greater decline in MMSE [10]. Similarly, a
randomized clinical trial on 150 healthy volunteers found
that antimuscarinics decreased delayed recall and suggested
differences in effects for different antimuscarinics depend-
ing on their selectivity for different muscarinic receptors;
specifically, the study identified significantly more important
impairment associated with the nonselective antimuscar-
inics (oxybutynin) as compared to the bladder-selective
one (darifenacin) [11]. A retrospective cohort study conduct-
ed in a nursing home population evaluated the long-term
functional and cognitive outcomes in elderly that received
antimuscarinics concomitant with cholinesterase inhibitors
and showed that those taking both medications had greater
rates of functional decline as compared to those who
received cholinesterase inhibitors alone [26].
Our study has important strengths as compared to these
previous studies investigating the association between anti-
muscarinics and cognitive decline. Our investigation
included more new users of antimuscarinics from a large
cohort of participants with different levels of cognitive func-
tion. All of the participants underwent extensive cognitive
testing using well-established and validated instruments.
Moreover, the testing was independent of antimuscarinic
use in our study; therefore, differential misclassification
or bias in our analyses is of lesser concern. In addition, our
analyses were conducted after careful consideration of con-
founding by using the IPTW approach to balance study
groups [27,28].
Given the nature of the data available and the issues
arising with repeated testing in longitudinal studies (i.e.,
practice effects), our study has some limitations. Repeated
testing and potential for learning effects, or ceiling/flooring
effects would potentially bias our results and underestimate
the true effect size [29,30]. With data collection scheduled
at enrollment and yearly after, and given that the question
on medication use asks about current medications taken by
the participant (i.e., all medications taken within 14 days of
the visit), we could not ascertain the exact date for
antimuscarinic initiation, and, therefore, the duration of
exposure to antimuscarinics for our users group. In
addition, some of the BAM users may have been
misclassified as nonusers in the situation in which they
started and stopped treatment between two consecutive
study visits. Finally, we were able to discern between
selective and nonselective antimuscarinics; however, we
could not differentiate between immediate-release and
extended-release nonselective antimuscarinic formulations.
Nevertheless, the bias resulting from these study design
issues would not change the interpretation for our results,
but would rather provide an underestimate for the true anti-
muscarinic effect on cognition. For instance, patients mis-
classified as nonusers, would be more likely those
experiencing adverse effects soon after antimuscarinic
initiation or those not tolerating these medications [31];
as a result, we can make the assumption that those partic-
ipants would also be more likely to experience cognitive
outcomes (i.e., decline) and be analyzed in the nonusers
group, thus biasing the results toward the null. Similarly,
our inability to restrict our analyses to those using
immediate-release formulations prevented us from seeing
a larger effect to that seen after restriction to nonselective
antimuscarinics. The potential for residual confounding in
our study remains given our inability to discern whether
antimuscarinic initiation was due to treatment of inconti-
nence as a prodromal symptom of cognitive decline. We
addressed this issue by incorporating a measure of
incontinence severity in our propensity score calculation
that allowed for balance between the groups. Another lim-
itation of our study is driven by the population recruited in
Table 3
Number needed to harm in relationship to bladder antimuscarinic use
Cognitive test NNH* (95% CI); all users NNH (95% CI); NS users
CDR Global scorey 22 (12–142) 21 (14–422)
MMSEz
All 13 (9–24) 10 (7–18)
Baseline cognitive status: normal 19 (9–442) 13 (7–90)
Baseline cognitive status: MCI 7 (3–16) 8 (5–136)
Baseline cognitive status: dementia 16 (9–131) 11 (7–34)
Abbreviations: NNH, number needed to harm; CI, confidence interval; NS, nonselective; CDR, Clinical Dementia Rating; MMSE, Mini–Mental State
Examination; MCI, mild cognitive impairment; OR, odds ratio.
*NNH derived from OR estimates [25].
yFrom normal to either MCI or dementia, or from MCI to dementia.
zAt least one-point decrease in MMSE score.
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the NACC cohort. Given the recruitment strategies that
differ among ADCs, participants enrolled in this cohort
are not necessarily a representative random sample for
the entire population of patients with MCI or dementia,
or for elderly with no cognitive impairment. Participants
in the NACC cohort, and therefore in our study, are in gen-
eral more educated, have higher income, and more likely to
receive care in academic hospitals and clinics. Therefore,
the generalizability of these findings to all community-
dwelling elderly may be limited. Replication of our results
in independent samples is needed.
In conclusion, our results support the growing evidence
for the association between antimuscarinic initiation and
cognitive decline in patients aged 65 years and older.
Importantly, our data show that patients with MCI might
be more sensitive to these antimuscarinic effects. Consid-
ering our findings suggesting that one would have to
treat fewer individuals to cause an adverse outcome
than to achieve the hoped-for benefit, prescribers
should consider this potential effect when contemplating
antimuscarinic initiation for their elderly patients
with urinary incontinence and should always weigh
the risks and the benefits of such treatment for each patient
individually.
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RESEARCH IN CONTEXT
1. Systematic review:We conducted a standard literature
review using PubMed to identify studies investigating
the association between bladder antimuscarinics and
cognitive decline in elderly patients. These previous
studies led to inconclusive results and they have impor-
tant limitations, including small sample size, short
follow-up, ormeasuring cognitive function with scales
less sensitive to longitudinal change.
2. Interpretation: We demonstrated a statistically sig-
nificant association between bladder antimuscarinic
initiation and different measures of cognitive func-
tion in adults aged 65 years and older; specifically,
our study showed that antimuscarinic initiation was
associated with worsening cognition. In addition,
we investigated association with specific cognitive
outcomes for which biologic plausibility supports
such effects. Importantly, our data showed that pa-
tients with mild cognitive impairment might be
more sensitive to these effects.
3. Future directions: Further investigations are needed
to explore the potential for a differential effect of
different types of BAM to allow for proper disease
management when medication is needed in this pop-
ulation.
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